Everything below concerns Peptide mapping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | Reversed-phase HPLC with UV detection | Separates target peptide from truncated and oxidised forms |
| Identity confirmation | LC-MS or ESI-MS | Compares observed and calculated molecular ion |
| Primary degradation route | Methionine oxidation | Forms the sulfoxide; monitored as an early-eluting peak |
| Short-term storage | 2 to 8 degrees Celsius | Applies to working vials and reconstituted portions |
| Common synonyms | ACTH(4–10) analogue, MEHFPGP | Descriptive names used in laboratory catalogues |
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
稳定性主要由水解与氧化两条路径支配。肽键在中性或弱酸性条件下相对稳定，遇到强碱或长时间高温则明显断裂；甲硫氨酸侧链容易被氧化成亚砜，使主峰前移并拉低实际含量。金属离子、光照和反复冻融会进一步促进降解或聚集。冻干粉在低温避光条件下可存放较长时间，配制后的水溶液通常需要冷藏并尽快用完。
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
In pharmacokinetics, bioavailability generally refers to the fraction of a drug that is absorbed systemically and is thus available to produce a biological effect. This is often measured by quantifying the "AUC". In order to determine the respective AUCs, the serum concentration vs. time plots are typically gathered using C-14 labelled drugs and AMS (accelerated mass spectrometry). Bioavailability can be measured in terms of "absolute bioavailability" or "relative bioavailability". Absolute bioavailability refers to the bioavailability of a drug when administered via an extravascular dosage form (i.e. oral tablet, suppository, subcutaneous, etc.) compared with the bioavailability of the same drug administered intravenously (IV). This is done by comparing the AUC of the non-intravenous dosage form with the AUC for the drug administered intravenously. This fraction is normalized by multiplying by each dosage form's respective dose. F abs = ( AUC non-IV AUC IV ) × ( Dose IV Dose non-IV )
where N0 is the number of atoms of the isotope in the original sample (at time t = 0, when the organism from which the sample was taken died), and N is the number of atoms left after time t. λ is a constant that depends on the particular isotope; for a given isotope it is equal to the reciprocal of the mean-life – i.e. the average or expected time a given atom will survive before undergoing radioactive decay. The mean-life, denoted by τ, of 14C is 8,267 years, so the equation above can be rewritten as:
=== Pancreatitis and pancreatic cancer === An association of the DPP-IV inhibitor class with pancreatic problems has been proposed, mainly based on case reports associated with the DPP-IV inhibitor sitagliptin and several incretin mimetics including exenatide. A 2013 study of the DPP-4 inhibitor sitagliptin reported found "worrisome changes in the pancreases of the rats that could lead to pancreatic cancer". A second paper by the same authors reported an increase in precancerous lesions in the pancreases of organ donors who had taken GLP-1 inhibitors. In response to these reports, the United States FDA and the European Medicines Agency each undertook independent reviews of all clinical and preclinical data related to the possible association of DPP-IV inhibitors with pancreatic cancer. In a joint letter to the New England Journal of Medicines, the agencies stated that "Both agencies agree that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with the current data. The FDA and the EMA have not reached a final conclusion at this time regarding such a causal relationship.
The commission noted that "the Russian intervention in Georgia was not limited to a “Blitz”-type action and was not solely focused on rescuing and evacuating Russian citizens." The commission said that "the constitutional obligation to protect Russian nationals [...] cannot serve as a justification for intervention under international law", adding that "Russian domestic law can [...] not be invoked as a justification for a breach of an international law." The commission suggested that "it seems abusive to rely on their need for protection as a reason for intervention, because Russia itself has created this reason for intervention". The commission concluded that "the Russian intervention in Georgia cannot be justified as a rescue operation for Russian nationals in Georgia."
Sources: en.wikipedia.org
=== Comic Books === Comics published during the Cold War provided both entertainment and political commentary. Themes of foreign wars, radiation, and social injustices were prevalent within the genre. Comics like Fantastic Four show American's relationship to the nuclear family unit, while other comics like Spider-Man and The Incredible Hulk show societal fears related to nuclear power and its effects. Other comics were less focused on fantastical elements and instead set their stories within Cold War events. Marines In Action was a comic series that ran from 1955 to 1957 that focuses on fictional characters within the Korean War. These comics were pro-war, which was a common sentiment among military centered stories.Golgo 13, a Japanese comic published since October 1968 also portrayed Cold War events like Fall of the Berlin Wall and Tiananmen Square protests from the perspective of the protagonist, a professional hitman hired by different powers.
The 2025 summit was the first summit for European Council President António Costa, British prime minister Keir Starmer, Canadian prime minister Mark Carney, and German chancellor Friedrich Merz. It was also the first and only summit for Japanese prime minister Shigeru Ishiba. The visit marked the first international visit to Canada for British prime minister Keir Starmer, Japanese prime minister Shigeru Ishiba, German chancellor Friedrich Merz, Australian prime minister Anthony Albanese, South Korean president Lee Jae Myung, and marked the second visit to Canada by Italian prime minister Giorgia Meloni and US president Donald Trump and the first visit since the 44th G7 summit in 2018. It marked the third visit to Canada for French president Emmanuel Macron and Ukrainian president Volodymyr Zelenskyy. In May, Mexican president Claudia Sheinbaum was invited to attend. Following the announcement, she told reporters that she had not decided if she would attend, but that it is "a possibility". On 30 May, Brazilian president Luiz Inácio Lula da Silva was invited and is expected to attend. In June, Crown Prince of Saudi Arabia Mohammed bin Salman was invited. However, on 12 June it was confirmed that he will not be attending the summit. Indonesian president Prabowo Subianto was initially invited by Mark Carney to attend the G7 summit, which he accepted. However, on 12 June, Prabowo announced that he would skip the summit and meet Singaporean prime minister Lawrence Wong, Vietnamese president Lương Cường, and Russian president Vladimir Putin instead.
Renovo Group plc was a biopharmaceutical company founded in 1998 and headquartered in Manchester, United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate, Juvista, all 100 of Renovo's staff were laid off in 2011. Although the company stopped all pharmaceutical development, it continued as a financial provider. In August 2014, Renovo Group plc was renamed Inspired Capital plc.
Sources: en.wikipedia.org
=== EC 2.3.2: Aminoacyltransferases === EC 2.3.2.1: D-glutamyltransferase EC 2.3.2.2: γ-glutamyltransferase EC 2.3.2.3: lysyltransferase EC 2.3.2.4: Now classified as EC 4.3.2.9, γ-glutamylcyclotransferase EC 2.3.2.5: glutaminyl-peptide cyclotransferase EC 2.3.2.6: leucyltransferase EC 2.3.2.7: aspartyltransferase EC 2.3.2.8: arginyltransferase EC 2.3.2.9: agaritine γ-glutamyltransferase EC 2.3.2.10: UDP-N-acetylmuramoylpentapeptide-lysine N6-alanyltransferase EC 2.3.2.11: alanylphosphatidylglycerol synthase EC 2.3.2.12: peptidyltransferase EC 2.3.2.13: protein-glutamine g-glutamyltransferase EC 2.3.2.14: D-alanine γ-glutamyltransferase EC 2.3.2.15: glutathione γ-glutamylcysteinyltransferase EC 2.3.2.16: lipid II:glycine glycyltransferase EC 2.3.2.17: N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-(N6-glycyl)-D-alanyl-D-alanine-diphosphoundecaprenyl-N-acetylglucosamine:glycine glycyltransferase EC 2.3.2.18: N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-(N6-triglycine)-D-alanyl-D-alanine-diphosphoundecaprenyl-N-acetylglucosamine:glycine glycyltransferase EC 2.3.2.19: ribostamycin:4-(γ-L-glutamylamino)-(S)-2-hydroxybutanoyl-[BtrI acyl-carrier protein] 4-(γ-L-glutamylamino)-(S)-2-hydroxybutanoate transferase EC 2.3.2.20: cyclo(L-leucyl-L-phenylalanyl) synthase EC 2.3.2.21: cyclo(L-tyrosyl-L-tyrosyl) synthase EC 2.3.2.22: cyclo(L-leucyl-L-leucyl) synthase EC 2.3.2.23: E2 ubiquitin-conjugating enzyme EC 2.3.2.24: (E3-independent) E2 ubiquitin-conjugating enzyme EC 2.3.2.25: N-terminal E2 ubiquitin-conjugating enzyme EC 2.3.2.26: HECT-type E3 ubiquitin transferase EC 2.3.2.27: RING-type E3 ubiquitin transferase EC 2.3.2.28: L-allo-isoleucyltransferase EC 2.3.2.29: aspartate/glutamate leucyltransferase EC 2.3.2.30: L-ornithine Nα-acyltransferase EC 2.3.2.31: RBR-type E3 ubiquitin transferase EC 2.3.2.32: cullin-RING-type E3 NEDD8 transferase EC 2.3.2.33: RCR-type E3 ubiquitin transferase EC 2.3.2.34: E2 NEDD8-conjugating enzyme EC 2.3.2.35: capsaicin synthase EC 2.3.2.36: RING-type E3 ubiquitin transferase (cysteine targeting)
=== Angle restraints === In addition to distance restraints, restraints on the torsion angles of the chemical bonds, typically the psi and phi angles, can be generated. One approach is to use the Karplus equation, to generate angle restraints from coupling constants. Another approach uses the chemical shifts to generate angle restraints. Both methods use the fact that the geometry around the alpha carbon affects the coupling constants and chemical shifts, so given the coupling constants or the chemical shifts, a qualified guess can be made about the torsion angles.
=== Dinoflagellates in the Adriatic Sea === The marine dinoflagellates: Prorocentrum micans, Lingulodinium polyedra, Gymnodinium sp., and Alexandrium tamarense, were collected from the Adriatic Sea during red-tide blooms and their 4-methyl sterol content was investigated. Dinosterol is the major component in P. micans, L. polyedra, and Gymnodinium strains, suggesting that dinosterol is a good biomarker because of its high abundance in most of the analyzed dinoflagellates.
Sources: en.wikipedia.org
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.
Oxidation of the methionine residue to the sulfoxide is a frequently reported change, and it usually appears as an earlier-eluting peak in reversed-phase chromatography. Backbone hydrolysis products can also accumulate in aqueous solution.
Liquid chromatography coupled with mass spectrometry is the usual approach, because the observed molecular ion can be compared with a calculated mass of about 813.9 Da. Retention time alone does not establish identity.
Solid peptide is best kept frozen at about minus 20 degrees Celsius in a sealed container with desiccant. It should be allowed to reach room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is discouraged.